Name: 글로벌 시장 동향
SKU: PH4089
Availability: InStock

보고서 요약(국문)

시장 개요
세계 대장암 치료제 시장은 2022년 136억 달러 규모에 달했으며, 2030년까지 181억 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 세계 대장암 치료제 시장은 2023년부터 2030년까지 연평균 3.7%의 성장률을 기록할 것으로 전망됩니다.
대장암 치료제는 대장 또는 직장에 발생하는 대장암 치료를 위한 다양한 치료 옵션을 포괄합니다. 이러한 약물은 종양 성장을 억제하고, 암세포의 전이를 막으며, 환자의 치료 결과를 개선합니다. 대장암 치료에 사용되는 주요 약물 계열 및 특정 약물에는 화학 요법, 면역 요법 및 기타 병용 요법이 포함됩니다.
또한, 대장암과 관련된 특정 유전자 변이 및 분자 경로의 규명은 표적 치료법 개발로 이어졌습니다. 연구자들은 치료 결과를 향상시키기 위해 다양한 약물을 병용하는 이점을 연구하고 있으며, 임상 시험을 통해 새로운 의약품과 치료법을 평가할 수 있게 됨에 따라 이러한 요인들이 향후 예측 기간 동안 대장암 치료제 시장 성장을 견인할 것으로 예상됩니다.
시장 동향
대장암 치료제에 대한 임상 시험의 증가는 예측 기간 동안 세계 대장암 치료제 시장의 성장을 촉진하고 있습니다.
2022년 9월, 화이자는 머크 KGaA, 오노 제약, 피에르 파브르와 협력하여 BEACON CRC 연구를 후원했습니다. 이 연구는 BRAF V600E라는 특정 유전자 변이를 가진 이전에 치료받은 전이성 대장암(mCRC) 환자를 대상으로 엔코라페닙 + 세툭시맙 ± 비니메티닙 병용 요법의 효과를 표준 치료법과 비교 평가했습니다.
무작위 3상 BEACON 연구(NCT02928224)는 엔코라페닙 + 세툭시맙 ± 비니메티닙 병용 요법이 대조군에 비해 전체 생존율과 객관적 반응률을 향상시켰음을 입증했습니다. 이 연구 결과는 BRAF V600E 돌연변이 전이성 대장암(mCRC) 치료에 있어 이 병용 요법의 효능에 대한 근거를 제공했습니다.
ctDNA 분석 결과, BRAF 및 EGFR 억제 후 MEK 억제 여부와 관계없이 MAPK 경로의 재활성화가 일반적인 내성 기전임을 보여주었습니다. RAS-MEK 신호 전달 경로의 후천적 돌연변이는 이중 요법(엔코라페닙 + 세툭시맙)으로 치료받은 환자에서 더 빈번하게 관찰되었으며, 수용체 신호 전달 강화는 삼중 요법(엔코라페닙 + 세툭시맙 + 비니메티닙)을 받은 환자에서 더 흔하게 나타났습니다.
대장암 치료제의 높은 비용은 예측 기간 동안 세계 대장암 치료제 시장의 성장을 저해하는 요인으로 작용하고 있습니다.
미국 질병통제예방센터(CDC)에 따르면, 대장암 치료 비용은 모든 암 유형 중 두 번째로 높으며, 전체 암 치료 비용의 12.6%를 차지합니다.

의료 서비스 비용은 237억 달러였으며, 처방약 비용은 6억 달러였습니다. 경구 처방약의 경우, 환자 1인당 평균 비용은 생애 마지막 해에 가장 높았고(1,400달러), 초기 치료 단계(400달러), 지속 치료 단계(약 200달러) 순으로 나타났습니다. 따라서 이러한 요인들로 인해 시장은 예측 기간 동안 어려움을 겪을 것으로 예상됩니다.
COVID-19 영향 분석
대장암 치료제 시장은 COVID-19 팬데믹으로 인해 상당한 차질을 겪었습니다. 전 세계 의료 시스템이 영향을 받아 암 검진, 진단 및 치료가 지연되었습니다. 대장암 치료제 임상 시험 또한 영향을 받아 환자 안전을 확보하고 팬데믹 관련 제한 사항을 준수하기 위해 많은 시험이 연기되거나 변경되었습니다.
결과적으로 신약 개발 및 출시가 둔화되었습니다. 또한 팬데믹의 경제적 영향으로 의료 시스템과 개인에게 재정적 제약이 발생하여 대장암 치료제의 가격 접근성과 이용 가능성에 영향을 미칠 수 있습니다. 이러한 복합적인 요인들은 대장암 치료제 시장의 역학 관계에 상당한 영향을 미쳤습니다.
러시아-우크라이나 분쟁 분석
러시아와 우크라이나 간의 지속적인 분쟁은 우크라이나의 대장암 치료제 공급에 심각한 영향을 미쳤습니다. 분쟁 이전에는 우크라이나가 암 치료제를 포함한 의약품 수입을 러시아에 크게 의존했습니다. 그러나 분쟁과 그에 따른 무역 제한으로 인해 이러한 의약품에 대한 접근이 제한되었고, 대장암 치료에 사용되는 의약품을 포함한 주요 의약품 부족 현상이 발생했습니다.
이러한 부족 현상으로 인해 환자들은 필수 의약품을 구할 수 없게 되어 치료가 지연되고 효과가 떨어지는 대체 의약품을 사용하게 되었습니다. 또한 수입 의약품 가격이 상승하여 환자와 의료 시스템 모두에게 부담이 가중되었습니다. 우크라이나 통화 가치 하락으로 인해 다른 국가에서 의약품을 구매하는 것이 더욱 어려워지면서 상황은 더욱 악화되었습니다.
러시아-우크라이나 분쟁이 대장암 치료제 시장에 미치는 영향은 글로벌 의약품 공급망의 잠재적 취약성을 보여줍니다. 이는 의약품 공급원을 다변화하고 자급률을 높여 수입 의약품 의존도를 줄이기 위해 국내 제약 산업을 발전시키는 것이 중요하다는 점을 강조합니다.
세분화 분석
세계 대장암 치료제 시장은 유형, 치료법, 최종 사용자, 유통 채널 및 지역별로 세분화됩니다.
혈관 내피 성장 인자(VEGF) 억제제 부문은 예측 기간 동안 시장을 주도할 것으로 예상됩니다.
혈관 내피 성장 인자(VEGF) 억제제 부문은 2022년 대장암 치료제 시장의 약 3분의 1을 차지하며 가장 높은 시장 점유율을 기록했습니다. 혈관 내피 성장 인자(VEGF) 억제제는 대장암 치료에 여러 가지 이점을 제공합니다. 이는 신생혈관 생성을 촉진하는 단백질인 VEGF의 활성을 차단함으로써 작용합니다.

예를 들어, 베바시주맙(BEV), 라무시루맙(RAM), 아플리버셉트(AFL)는 2차 항암화학요법으로 치료받는 전이성 직장암(mCRC) 환자에게 널리 사용됩니다.
또한, VEGF 억제제는 직장암 치료에서 항암화학요법과 병용하여 사용되는 경우가 많습니다. 연구에 따르면 VEGF 억제제를 항암화학요법에 추가하면 항암화학요법 단독 치료에 비해 치료 반응률과 전체 생존율이 향상되는 것으로 나타났습니다. 이러한 병용 요법은 보다 효과적인 종양 제어와 환자 예후 개선으로 이어질 수 있습니다.
지역 분석
시장 참여자들의 인수 증가, 직장암 발병률 증가, 그리고 시장 참여자들의 신제품 출시 증가는 북미 지역을 주도하고 있습니다.
북미는 카테터 안정화 장치 시장의 약 3분의 1을 차지하며 시장을 주도할 것으로 예상되며, 미국이 가장 큰 비중을 차지할 것입니다.

미국암협회(ACS)의 최근 '2023년 대장암 통계' 보고서에 따르면, 미국 내 대장암 발병 추세에 주목할 만한 변화가 나타났습니다. 이 보고서는 진행성 대장암(CRC) 진단을 받은 사람의 비율이 2000년대 중반 52%에서 2019년 60%로 증가했다고 밝혔습니다.
또한, 55세 미만 환자의 진단 비율은 1995년 11%에서 2019년 20%로 두 배 이상 증가하여 젊은 연령층에서 대장암 발병률이 우려스러운 수준으로 증가하고 있음을 보여줍니다. 보고서는 2023년 미국에서 약 153,020명이 대장암 진단을 받고 52,550명이 사망할 것으로 추정했습니다. 이러한 수치는 대장암이 미치는 심각한 영향과 지속적인 위협을 강조합니다.

또한, 2023년 3월 13일, 화이자(Pfizer Inc.)와 시젠(Seagen Inc.)은 화이자가 혁신적인 항암제를 발굴, 개발 및 상용화하는 글로벌 생명공학 기업인 시젠을 주당 229달러 현금, 총 430억 달러의 기업 가치로 인수하는 최종 합병 계약을 체결했다고 발표했습니다.
따라서 위와 같은 요인들로 인해 북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
경쟁 환경
시장의 주요 글로벌 기업으로는 제넨텍(Genentech, Inc.), 일라이 릴리(Eli Lilly, and Company), 화이자(Pfizer), 애보트 연구소(Abbott Laboratories), 사노피(Sanofi S.A.), 브리스톨-마이어스 스큅(Bristol-Myers Squibb), 암젠(Amgen), 머크(Merck & Co., Inc.), 테바(Teva Pharmaceuticals), 노바티스(Novartis), 글락소스미스클라인(GlaxoSmithKline), 오닉스(Onyx) 등이 있습니다.
보고서 구매 이유

• 유형, 치료법, 최종 사용자, 유통 채널 및 지역별 글로벌 대장암 치료제 시장 세분화를 시각화하고 주요 상업적 자산과 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 대장암 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 대장암 치료제 시장 보고서는 약 69개의 표, 72개의 그림, 195페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Colorectal Cancer Drugs Market reached US$ 13.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 18.1 billion by 2030. The Global Colorectal Cancer Drugs Market is expected to exhibit a CAGR of 3.7% during the forecast period 2023-2030.
Colorectal cancer drugs encompass a range of therapeutic options for treating colorectal cancer, which affects the colon or rectum. These drugs inhibit tumor growth, prevent cancer cells from spreading, and improve patient outcomes. The major drug classes and specific medications used to treat colorectal cancer include chemotherapy, immunotherapy, and other combination drugs.
Furthermore, the identification of specific genetic mutations and molecular pathways implicated in colorectal cancer has led to the development of targeted therapies; researchers are exploring the benefits of combining different drugs to enhance treatment outcomes and the conduct of clinical trials allows for the evaluation of new medicines and treatment regimens are the factors expected to drive the colorectal cancer drugs over the forecast period.
Market Dynamics
The increasing clinical trial for colorectal cancer drugs is boosting the growth of the Global Colorectal Cancer Drug Market during the forecast period.
In September 2022, Pfizer, in collaboration with Merck KGaA, ONO Pharmaceutical, and Pierre Fabre, sponsored the BEACON CRC study. The study evaluated the effectiveness of encorafenib + cetuximab ± binimetinib regimens compared to standard of care in patients with previously treated metastatic colorectal cancer (mCRC) with a specific genetic mutation called BRAF V600E.
The randomized phase III BEACON study (NCT02928224) demonstrated that the encorafenib + cetuximab ± binimetinib regimens improved overall survival and objective response rate compared to the control group. This finding provided evidence for the efficacy of this combination therapy in treating BRAF V600E-mutant mCRC.
The ctDNA analysis demonstrated that reactivation of the MAPK pathway is a common resistance mechanism after inhibiting BRAF and EGFR, with or without MEK inhibition. Acquired mutations in the RAS-MEK signaling pathway were more frequently observed in patients treated with the doublet regimen (encorafenib + cetuximab), while enhanced receptor signaling was more prevalent in those receiving the triplet regimen (encorafenib + cetuximab + binimetinib).
The high costs of drugs for colorectal cancer are hampering the growth of the Global Colorectal Cancer Drugs Market in the forecast period.
According to the Centers for Disease Control and Prevention, the treatment expenses for colorectal cancer rank second highest among all types of cancer, comprising 12.6% of the total costs associated with cancer treatment.
Medical services accounted for $23.7 billion, while prescription drugs contributed $0.6 billion to these expenses. Furthermore, in terms of oral prescription drugs, the average costs per patient were found to be the greatest during the final year of life ($1,400), followed by the initial care phase ($400), and the continuing care phase (approximately $200). Thus, owing to the above factors, the market is expected to hamper over the forecast period.
COVID-19 Impact Analysis
The colorectal cancer drugs market has experienced significant disruptions due to the COVID-19 pandemic. Healthcare systems globally have been impacted, leading to delays in cancer screenings, diagnosis, and treatments. Clinical trials for colorectal cancer drugs were also affected, with many being postponed, delayed, or modified to ensure patient safety and comply with pandemic-related restrictions.
Consequently, the development and introduction of new drugs have been slowed down. Additionally, the economic impact of the pandemic has created financial constraints for healthcare systems and individuals, potentially influencing the affordability and accessibility of colorectal cancer drugs. These combined factors have notably impacted the dynamics of the colorectal cancer drugs market.
Russia-Ukraine Conflict Analysis
The ongoing conflict between Russia and Ukraine has significantly impacted the availability of colorectal cancer drugs in Ukraine. Before the conflict, Ukraine relied heavily on Russia to import pharmaceuticals, including cancer drugs. However, following the conflict and subsequent trade restrictions, access to these drugs became limited, leading to a shortage of critical medications, including those used to treat colorectal cancer.
As a result of this shortage, patients have been unable to access essential drugs, leading to treatment delays and the use of alternative, less effective drugs. Additionally, the cost of imported drugs increased, making them less affordable for patients and healthcare systems. The situation was further compounded by the devaluation of the Ukrainian currency, making purchasing drugs from other countries more challenging.
The impact of the Russia-Ukraine conflict on the colorectal cancer drugs market highlights the potential vulnerabilities of global pharmaceutical supply chains. It underscores the importance of diversifying the sources of drug supplies and developing local pharmaceutical industries to enhance self-sufficiency and reduce dependence on imported drugs.
Segment Analysis
The Global Colorectal Cancer Drugs Market is segmented based on type, therapy, end user, distribution channel, and region.
The vascular endothelial growth factor (VEGF) inhibitors segment is expected to dominate the market over the forecast period.
The vascular endothelial growth factor (VEGF) inhibitors segment accounted for the highest market stake, accounting for approximately 1/3rd of the colorectal cancer drugs market in 2022. Vascular endothelial growth factor (VEGF) inhibitors have several advantages in the treatment of colorectal cancer. It works by blocking the activity of VEGF, a protein that promotes the formation of new blood vessels (angiogenesis).
For instance, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second-line chemotherapy.
Additionally, VEGF inhibitors are often used in combination with chemotherapy in the treatment of colorectal cancer. Studies have shown that adding VEGF inhibitors to chemotherapy regimens improves treatment response rates and overall survival compared to chemotherapy alone. This combination therapy approach can lead to more effective tumor control and increased patient outcomes.
Geographical Analysis
The increasing acquisitions by the market players, the growing prevalence of colorectal cancer, and rising product launches by the market players dominate the North American region.
North America is expected to dominate the catheter stabilization devices market, accounting for around 1/3rd of this market, with the U.S. being the major contributor.
According to the recent Colorectal Cancer Statistics 2023 report by the American Cancer Society (ACS), there has been a notable shift in colorectal cancer trends in the United States. The report reveals that the proportion of individuals diagnosed with advanced-stage colorectal cancer (CRC) has increased from 52% in the mid-2000s to 60% in 2019.
Moreover, the diagnoses of individuals under the age of 55 have doubled from 11% in 1995 to 20% in 2019, indicating a concerning rise in colorectal cancer among younger age groups. Overall, the report estimates that in 2023, approximately 153,020 people in the United States will receive a diagnosis of colorectal cancer, and 52,550 individuals will succumb to the disease. These figures highlight the significant impact and continued threat posed by colorectal cancer.
Furthermore, on March 13, 2023, Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
Hence , the North American region is expected to hold the largest market share over the forecast period due to the above factors.
Competitive Landscape
The major global players in the market include Genentech, Inc., Eli Lilly, and Company, Pfizer, Abbott Laboratories, Sanofi S.A., Bristol-Myers Squibb, Amgen, Bristol-Myers Squib, Merck & Co., Inc., Teva Pharmaceuticals, Novartis, GlaxoSmithKline, Onyx among others.
Why Purchase the Report?
• To visualize the Global Colorectal Cancer Drugs Market segmentation based on the type, therapy, end user, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of colorectal cancer drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Colorectal Cancer Drugs Market Report Would Provide Approximately 69 Tables, 72 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Therapy
3.3. Snippet by End User
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing clinical trial for colorectal cancer drugs
4.1.2. Restraints
4.1.2.1. The high costs of drugs for colorectal cancer
4.1.3. Opportunity
4.1.3.1. Growing focus on developing targeted therapies that specifically address the molecular characteristics
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Epidermal Growth Factor Receptor (EGFR) Inhibitors
8.4. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
8.5. BRAF Or MEK Inhibitors
8.6. Tyrosine Kinase (TKI) Inhibitors
8.7. Immunomodulators
8.8. Others
9. By Therapy
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
9.1.2. Market Attractiveness Index, By Therapy
9.2. Immunotherapy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Targeted therapy
9.4. Chemotherapy
9.5. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospital*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Research Institute
10.5. Others
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. The U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. The U.K.
12.3.7.3. France
12.3.7.4. Italy
12.3.7.5. Spain
12.3.7.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. Brazil
12.4.7.2. Argentina
12.4.7.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.7.1. China
12.5.7.2. India
12.5.7.3. Japan
12.5.7.4. Australia
12.5.7.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Genentech, Inc.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Eli Lilly and Company
14.3. Pfizer
14.4. Sanofi S.A.
14.5. Bristol-Myers Squibb
14.6. Amgen
14.7. Merck & Co., Inc.
14.8. Teva Pharmaceuticals
14.9. Novartis
14.10. GlaxoSmithKline
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Genentech, Inc., 4.	Key Developments, Eli Lilly and Company, Pfizer, Sanofi S.A., Bristol-Myers Squibb, Amgen, Merck & Co., Inc., Teva Pharmaceuticals, Novartis, GlaxoSmithKline

표 목록 (Tables)

List of Tables Table 1 Global Colorectal Cancer Drugs Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Colorectal Cancer Drugs Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Colorectal Cancer Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Colorectal Cancer Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Colorectal Cancer Drugs Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Colorectal Cancer Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 7 Global Colorectal Cancer Drugs Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Colorectal Cancer Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 9 Global Colorectal Cancer Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Colorectal Cancer Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 11 Global Colorectal Cancer Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Colorectal Cancer Drugs Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Colorectal Cancer Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 14 North America Colorectal Cancer Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 15 North America Colorectal Cancer Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 16 North America Colorectal Cancer Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Colorectal Cancer Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 18 Europe Colorectal Cancer Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 19 Europe Colorectal Cancer Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 Europe Colorectal Cancer Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Colorectal Cancer Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Colorectal Cancer Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Colorectal Cancer Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Colorectal Cancer Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Colorectal Cancer Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 26 South America Colorectal Cancer Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 27 South America Colorectal Cancer Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 28 South America Colorectal Cancer Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Colorectal Cancer Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Colorectal Cancer Drugs Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Colorectal Cancer Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Colorectal Cancer Drugs Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 Roche: Overview

Table 34 Roche: Product Portfolio

Table 35 Roche: Key Developments

Table 36 Merck & Co., Inc.: Overview

Table 37 Merck & Co., Inc.: Product Portfolio

Table 38 Merck & Co., Inc.: Key Developments

Table 39 Bristol-Myers Squibb: Overview

Table 40 Bristol-Myers Squibb: Product Portfolio

Table 41 Bristol-Myers Squibb: Key Developments

Table 42 Amgen: Overview

Table 43 Amgen: Product Portfolio

Table 44 Amgen: Key Developments

Table 45 Pfizer: Overview

Table 46 Pfizer: Product Portfolio

Table 47 Pfizer: Key Developments

Table 48 Eli Lilly and Company: Overview

Table 49 Eli Lilly and Company: Product Portfolio

Table 50 Eli Lilly and Company: Key Developments

Table 51 Bayer: Overview

Table 52 Bayer: Product Portfolio

Table 53 Bayer: Key Developments

Table 54 Taiho Oncology: Overview

Table 55 Taiho Oncology: Product Portfolio

Table 56 Taiho Oncology: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Colorectal Cancer Drugs Market Share, By Drug Class, 2024 & 2033 (%)

Figure 3 Global Colorectal Cancer Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 4 Global Colorectal Cancer Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Colorectal Cancer Drugs Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Colorectal Cancer Drugs Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 7 Chemotherapy Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 8 Targeted Therapy Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 9 Immunotherapy Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 10 Global Colorectal Cancer Drugs Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 11 Intravenous Route of Administration in Global Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 12 Oral Route of Administration in Global Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 13 Global Colorectal Cancer Drugs Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 14 Hospital Pharmacies Distribution Channel in Global Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 15 Retail Pharmacies Distribution Channel in Global Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 16 Online Pharmacies Distribution Channel in Global Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 17 Global Colorectal Cancer Drugs Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 18 North America Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 19 North America Colorectal Cancer Drugs Market Share, By Drug Class, 2024 & 2033 (%)

Figure 20 North America Colorectal Cancer Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 21 North America Colorectal Cancer Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 22 North America Colorectal Cancer Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 23 Europe Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 24 Europe Colorectal Cancer Drugs Market Share, By Drug Class, 2024 & 2033 (%)

Figure 25 Europe Colorectal Cancer Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 26 Europe Colorectal Cancer Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 27 Europe Colorectal Cancer Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 28 Asia-Pacific Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 29 Asia-Pacific Colorectal Cancer Drugs Market Share, By Drug Class, 2024 & 2033 (%)

Figure 30 Asia-Pacific Colorectal Cancer Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 31 Asia-Pacific Colorectal Cancer Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 32 Asia-Pacific Colorectal Cancer Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 33 South America Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 34 South America Colorectal Cancer Drugs Market Share, By Drug Class, 2024 & 2033 (%)

Figure 35 South America Colorectal Cancer Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 36 South America Colorectal Cancer Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 37 South America Colorectal Cancer Drugs Market Share, By Country, 2024 & 2033 (%)

Figure 38 Middle East and Africa Colorectal Cancer Drugs Market Value, 2022-2033 (US$ Billion)

Figure 39 Middle East and Africa Colorectal Cancer Drugs Market Share, By Drug Class, 2024 & 2033 (%)

Figure 40 Middle East and Africa Colorectal Cancer Drugs Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 41 Middle East and Africa Colorectal Cancer Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 42 Roche: Financials

Figure 43 Merck & Co., Inc.: Financials

Figure 44 Bristol-Myers Squibb: Financials

Figure 45 Amgen: Financials

Figure 46 Pfizer: Financials

Figure 47 Eli Lilly and Company: Financials

Figure 48 Bayer: Financials

Figure 49 Taiho Oncology: Financials

세계 대장암 치료제 시장 – 2023-2030

Global Colorectal Cancer Drugs Market - 2023-2030